GLG News Analyses of the following article:

Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug

view article

Published at: www.pipelinereview.com

Joseph Bass, Kettering Professor & Chief Div of Endocrinology

Joseph BassKettering Professor & Chief Div of EndocrinologyNORTHWESTERN UNIVERSITY What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Another Glinide: Where's the Beef?

March 28, 2008

Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel antagonist.  The old problems likely will still appear: hypoglycemia, weight gain, and possibly progression of pancreatic failure/cell death.

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
9 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software